Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Cholesterol treatment with statins: who is left out and who makes it to goal?

Franks P, Tancredi D, Winters P, Fiscella K.

BMC Health Serv Res. 2010 Mar 17;10:68. doi: 10.1186/1472-6963-10-68.

2.

The role of usual source of care in cholesterol treatment.

Winters P, Tancredi D, Fiscella K.

J Am Board Fam Med. 2010 Mar-Apr;23(2):179-85. doi: 10.3122/jabfm.2010.02.090084.

3.

Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.

Mann D, Reynolds K, Smith D, Muntner P.

Ann Pharmacother. 2008 Sep;42(9):1208-15. doi: 10.1345/aph.1L181. Epub 2008 Jul 22.

PMID:
18648016
5.
6.

Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy.

Quilliam BJ, Perez HE, Andros V, Jones P.

J Manag Care Pharm. 2004 May-Jun;10(3):244-50.

7.
8.
9.

Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.

Bradford WD, Kleit AN, Nietert PJ, Ornstein S.

Clin Ther. 2006 Dec;28(12):2105-18; discussion 2104.

PMID:
17296467
12.

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults.

Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J.

Am J Cardiol. 1998 Jul 1;82(1):61-5.

PMID:
9671010
13.

Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study.

Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, Zhang Q, Yan P.

Curr Med Res Opin. 2008 Jul;24(7):1951-63. doi: 10.1185/03007990802138731 . Epub 2008 Jun 10.

PMID:
18547466
15.

Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.

González CA, Rubio-Guerra AF, Pavía A, Redding FJ, Cervantes JL, Zacarías JL, Yza R, Carranza J, Fernández P, Morales E, Robles FJ, Leyva JL, Rodríguez L.

Clin Drug Investig. 2007;27(5):333-7.

PMID:
17451281
16.

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.

PMID:
10819699
17.

The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D.

Am J Cardiovasc Drugs. 2006;6(6):383-91.

PMID:
17192128
19.

Low cholesterol, statins and outcomes in patients with first-ever acute ischemic stroke.

Koton S, Molshatzki N, Bornstein NM, Tanne D.

Cerebrovasc Dis. 2012;34(3):213-20. doi: 10.1159/000342302. Epub 2012 Sep 18.

PMID:
23006641
20.

Lipid management and cholesterol goal attainment in Norway.

Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgström F, Jönsson L.

Am J Cardiovasc Drugs. 2006;6(2):121-8.

PMID:
16555865

Supplemental Content

Support Center